Objective: Several cytokines, particularly IL-2 and interferons, are thought to be effective in the palliative therapy of neoplastic effusions. We report on the activity and toxicity of intracavitary administration of low-dose IL-2 in a case series of 100 cancer patients with neoplastic effusions. Methods: One hundred patients with advanced solid tumors and neoplastic effusions underwent IL-2 intracavitary injection as first-line treatment. The most common sites of fluid accumulation were pleura (n = 68), peritoneum (n = 21) and pericardium (n = 11). Breast cancer, lung cancer and mesothelioma were the most frequent neoplasms in our series. One cycle consisted of intracavitary IL-2 at 6,000,000 IU on days 1 and 7. Results: According to Paladine’s criteria, an objective clinical response was achieved in 72% (complete response in 27% and partial response in 45%), with a median duration of 5 months (range: 1–11 months). The peritoneum was the least responsive site for neoplastic effusion reduction. IL-2 intracavitary injection was well tolerated in all patients; the only toxicity observed was fever >38°C in 6% of the patients. Conclusion: This study shows that intracavitary injection of IL-2 represents a feasible, well-tolerated and effective therapy of neoplastic fluid accumulation. Further studies are needed in order to compare the effectiveness of intracavitary IL-2 with other standard treatments.

Keywords:
Interleukin-2, Intracavitary therapy, Palliative treatment, Neoplastic effusions
1.
Weichselbaum R, Marck A, Hellman S: Pathogenesis of pleural effusion in the carcinoma of the breast. Int J Radiat Oncol Biol Phys 1977;2:963–968.
2.
Thomas JM, Redding WH, Sloane JP: The spread of breast cancer. Importance of the intrathoracic lymphatic route and its relevance to treatment. Br J Cancer 1979;40:540–544.
3.
Nagy JA, Morgan ES, Herzberg KT, Manseau EJ, Dvorak AM, Dvorak HF: Pathogenesis of ascites tumor growth: Angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. Cancer Res 1995;55:376–385.
4.
Valle MT, Degl’Innocenti ML, Bertelli R, Facchetti P, Perfumo F, Fenoglio D, Kunkl A, Gusmano R, Manca F: Antigen-presenting function of human peritoneum mesothelial cells. Clin Exp Immunol 1995;101:172–176.
5.
Chernow B, Sahn SA: Carcinomatous involvement of the pleura. Am J Med 1977;63:695–702.
6.
Pass HL: Malignant pleural and pericardial effusions; in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, 5. Philadelphia, Lippincott- Raven, 1997, pp 2586–2598.
7.
Fentiman IS, Millis R, Sexton S, Hayward JL: Pleural effusion in breast cancer: A review of 105 cases. Cancer 1981;47:2087–2092.
8.
Fracchia AA, Knapper WH, Carey JT, Farrow JH: Intrapleural chemotherapy for effusion from metastatic breast carcinoma. Cancer 1970;26:626–629.
9.
Garrison RN, Kaelin LD, Galloway RH, Heuser LS: Malignant ascites. Clinical and experimental observations. Ann Surg 1986;203:644–651.
10.
Zeehner LC, Hogstraten B: Malignant effusions and their management. Semin Oncol Nurs 1985;1:259.
11.
Paladine W, Cunningham TJ, Sponzo R, Donavan M, Olson K, Horton J: Intracavitary bleomycin in the management of malignant effusions. Cancer 1976;38:1903–1908.
12.
Zaloznik AJ, Oswald SG, Langin M: Intrapleural tetracycline in malignant pleural effusions. A randomized study. Cancer 1983;51:752–755.
13.
Ostrowski MJ: An assessment of the long-term results of controlling the reaccumulation of malignant effusions using intracavitary bleomycin. Cancer 1986;57:721–727.
14.
Gravelyn TR, Michelson MK, Gross BH, et al: Tetracycline pleurodesis for malignant pleural effusions. A 10-year retrospective study. Cancer 1987;59:1973–1977.
15.
Alberts DS, Chen HS, Mayersohn M, et al: Bleomycin pharmacokinetics in man: Intracavitary administration. Cancer Chemother Pharmacol 1979;2:127–132.
16.
Ruckedeschel JC, Moores D, Lee JY, et al: Intrapleural therapy for malignant pleural effusion: A randomized comparison of bleomycin and tetracycline. Chest 1991;100:1528–1535.
17.
Barni S, Lissoni P, Cattaneo G, et al: Interferon alpha-2b in the treatment of pleural and peritoneal neoplastic effusions. J Cancer Res Clin Oncol 1990;116(suppl):306.
18.
Rosso R, Rimoldi R, Salvati F, et al: Intrapleural natural beta interferon in the treatment of malignant pleural effusions. Oncology 1988;45:253–256.
19.
Reath U, Schmid H, Hofman J, et al: Intraperitoneal (i.p.) application of recombinant human tumor necrosis factor (rHn-TNF) as an effective palliative treatment of malignant ascites from ovarian cancer and gastroenteropancreatic carcinomas. Proc Am Soc Clin Oncol 1989;703:181.
20.
Yasumoto K, Miwazaki K, Nagashima A, et al: Induction of lymphokine-activated killer cells by intrapleural instillation of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer. Cancer Res 1987;47:2184–2187.
21.
Lissoni P, Barni S, Ardizzoia A, et al: Intracavitary administration of interleukin-2 as palliative therapy for neoplastic effusions. Tumori 1992;78:118–120.
22.
Viallat JR, Boutin C, Rey F, et al: Intrapleural immunotherapy with escalating doses of interleukin-2 in metastatic pleural effusions. Cancer 1993;71:4067–4071.
23.
Astoul P, Viallat JR, Laurent JC, et al: Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion. Chest 1993;103:209–213.
24.
Kessinger A, Wighton RS: Intracavitary bleomycin and tetracycline in the management of malignant pleural effusions: A randomized study. J Surg Oncol 1987;36:81–86.
25.
Moores DWO: Malignant pleural effusion. Semin Oncol 1991;18:59–68.
26.
Bjermer L, Gronberg H, Roos G, et al: Interleukin-2 administration intravenous and intrapleurally in a patient with primary pulmonary adenocarcinoma. Biotherapy 1993;6:1–7.
27.
Robinson BWS, Bowman RU, Christmas TI: Clinical experience using immunotherapy (IL-2/LAK cells or interferon alpha 2a) in malignant mesothelioma (abstract 38). 1st International Mesothelioma Conference, Paris, 1991.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.